Vaccines

NFL legend Brett Favre reports gains from an experimental Parkinson's drug, but what does the science say about this potential breakthrough treatment?

The biopharma posts record Q1 revenue and profit, driven by its flagship DefenCath and a key acquisition, while a promising pipeline signals future growth.

A new six-month semaglutide implant is entering clinical trials, aiming to solve the adherence crisis plaguing GLP-1 drugs like Ozempic and Wegovy.

A $25M payment from partner Chiesi catapults Protalix to a profitable quarter, funding a promising new gout therapy and a broader rare disease strategy.

A new alliance aims to develop first-in-class drugs for Alzheimer's and Parkinson's by targeting chronic brain inflammation, a key driver of disease.

With a novel drug for schizophrenia and deep financial backing, LB Pharmaceuticals is advancing a promising new therapy for complex mental illnesses.

As its oesophageal cancer vaccine enters trials, Infinitopes hires a top CSO with a track record of bringing breakthrough therapies to market.

A new drug targeting the root cause of sebum production shows promise in clinical trials, offering hope for millions of moderate to severe acne sufferers.

Anaveon reveals promising ASCO data for its cancer drug ANV600, yet puts the asset on the market to fund a bold new focus on autoimmune diseases.

The specialty manufacturer reports a 46% profit surge, fueled by strong demand for its key drug and a major distributor's comeback. What's next?

A three-month FDA delay for a new LEQEMBI injection highlights the high-stakes race for a convenient Alzheimer's therapy and its complex safety hurdles.

Facing financial pressures, the biotech divests a key cancer program, repays debt, and now explores all options to maximize value for its remaining pipeline.

The biotech supplier swung to profitability and positive cash flow, driven by a major cost overhaul and strong demand in its core nucleic acid business.

A new health campaign uses emotional appeals to boost adult vaccination in Southeast Asia, highlighting the complex role of pharma in public health.

A new drug shows major promise for a painful heart condition, with pivotal study results accepted by a top journal and a final-stage trial speeding ahead.

Dr. Richard Berger celebrates a quarter-century of pioneering outpatient joint surgery, a practice that has transformed orthopedic care and patient recovery.

With a key FDA decision looming, Cristcot hires Rayna Herman to lead the commercial strategy for its first-in-class ulcerative colitis therapy, ngHCA.

With a promising cancer pipeline, Crescent Biopharma heads to key May conferences to prove its strategy against fierce competition in the bispecific and ADC markets.

As EyePoint's losses widen to fund its lead drug, DURAVYU, the company is on the cusp of pivotal trial results that could redefine retinal disease treatment.

A new report reveals a dramatic shift in Alzheimer's drug development, with 75% of trials now targeting pathways beyond amyloid for a new age of treatment.